AKI-话题@MedSci

#AKI#

70篇内容 | 2771人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1341131, encodeId=bb801341131ef, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=Blueprint的Ayvakit成为美国获批治疗罕见胃肠道间质瘤突变的靶向疗法, objectType=article, longId=186045, objectId=eda21860459a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eda21860459a, replyNumber=0, likeNumber=80, createdTime=2020-01-12, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eda21860459a, moduleTitle=Blueprint的Ayvakit成为美国获批治疗罕见胃肠道间质瘤突变的靶向疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eda21860459a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341130, encodeId=2c581341130c4, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=礼来的聚乙二醇白细胞介素-10（pegilodecakin）在胰腺癌临床试验中失败, objectType=article, longId=181646, objectId=23b918164627, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23b918164627, replyNumber=0, likeNumber=81, createdTime=2019-10-22, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23b918164627, moduleTitle=礼来的聚乙二醇白细胞介素-10（pegilodecakin）在胰腺癌临床试验中失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23b918164627)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341129, encodeId=086a1341129d6, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=免疫疗法pegilodecakin在胰腺癌中的III期研究未能达到总体生存的主要终点, objectType=article, longId=181451, objectId=7dae1814517d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7dae1814517d, replyNumber=0, likeNumber=71, createdTime=2019-10-19, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7dae1814517d, moduleTitle=免疫疗法pegilodecakin在胰腺癌中的III期研究未能达到总体生存的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7dae1814517d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341128, encodeId=354e1341128ca, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=J Endod：Gow-Gates, Vazirani-Akinosi和Mental Incisive神经阻滞对有症状不可逆牙髓炎的麻醉效果比较, objectType=article, longId=180412, objectId=e63e18041230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e63e18041230, replyNumber=0, likeNumber=62, createdTime=2019-10-04, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e63e18041230, moduleTitle=J Endod：Gow-Gates, Vazirani-Akinosi和Mental Incisive神经阻滞对有症状不可逆牙髓炎的麻醉效果比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e63e18041230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341127, encodeId=bdeb134112e5e, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=Lancet oncol：Pegilodecakin联合抗PD-1单克隆抗体是否可为晚期实体肿瘤提供新的治疗机会？, objectType=article, longId=180124, objectId=a26018012453, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a26018012453, replyNumber=0, likeNumber=49, createdTime=2019-09-28, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a26018012453, moduleTitle=Lancet oncol：Pegilodecakin联合抗PD-1单克隆抗体是否可为晚期实体肿瘤提供新的治疗机会？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a26018012453)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341126, encodeId=808513411261f, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=Harmony Biosciences的嗜睡症治疗药物Wakix获得FDA批准, objectType=article, longId=177799, objectId=8b831e7799a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b831e7799a0, replyNumber=0, likeNumber=68, createdTime=2019-08-18, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b831e7799a0, moduleTitle=Harmony Biosciences的嗜睡症治疗药物Wakix获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b831e7799a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341125, encodeId=cd74134112505, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=庆大霉素诱导的AKI大鼠给予麝香酮骨髓间充质干细胞可提高其治疗效果, objectType=article, longId=165106, objectId=8ded165106a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ded165106a9, replyNumber=0, likeNumber=73, createdTime=2019-04-29, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ded165106a9, moduleTitle=庆大霉素诱导的AKI大鼠给予麝香酮骨髓间充质干细胞可提高其治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ded165106a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341124, encodeId=a4801341124d4, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=英国NICE推荐Akice公司的反义寡核苷酸药物Tegsedi用于治疗罕见遗传病：转甲状腺素相关的淀粉样蛋白变性, objectType=article, longId=164501, objectId=d2851645017f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2851645017f, replyNumber=0, likeNumber=52, createdTime=2019-04-19, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2851645017f, moduleTitle=英国NICE推荐Akice公司的反义寡核苷酸药物Tegsedi用于治疗罕见遗传病：转甲状腺素相关的淀粉样蛋白变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2851645017f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341123, encodeId=63c6134112388, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=Daiichi Sankyo的EZH1/2双重抑制剂Valemetostat获得日本厚生劳动省SAKIGAKE指定，用于治疗复发/难治性外周T细胞淋巴瘤, objectType=article, longId=163986, objectId=5b4b163986c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b4b163986c0, replyNumber=0, likeNumber=73, createdTime=2019-04-11, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b4b163986c0, moduleTitle=Daiichi Sankyo的EZH1/2双重抑制剂Valemetostat获得日本厚生劳动省SAKIGAKE指定，用于治疗复发/难治性外周T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b4b163986c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341122, encodeId=f6ea134112291, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=成纤维细胞生长因子受体酪氨酸激酶抑制剂E7090治疗胆管癌，获得日本厚生劳动省的Sakigake指定, objectType=article, longId=163899, objectId=93891638993f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93891638993f, replyNumber=0, likeNumber=67, createdTime=2019-04-10, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93891638993f, moduleTitle=成纤维细胞生长因子受体酪氨酸激酶抑制剂E7090治疗胆管癌，获得日本厚生劳动省的Sakigake指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93891638993f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341121, encodeId=4fd5134112113, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=SanBio宣布其再生细胞疗法SB623治疗创伤性脑损伤，获得日本厚生劳动省Sakigake指定, objectType=article, longId=163898, objectId=0ea91638984f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ea91638984f, replyNumber=0, likeNumber=73, createdTime=2019-04-10, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ea91638984f, moduleTitle=SanBio宣布其再生细胞疗法SB623治疗创伤性脑损伤，获得日本厚生劳动省Sakigake指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ea91638984f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341120, encodeId=3bab134112082, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=Crit Care：利尿剂有助于AKI重症患者成功停用CRRT？, objectType=article, longId=152366, objectId=6206152366be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6206152366be, replyNumber=0, likeNumber=78, createdTime=2018-11-01, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6206152366be, moduleTitle=Crit Care：利尿剂有助于AKI重症患者成功停用CRRT？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6206152366be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341119, encodeId=64b2134111966, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=澳大利亚TGA批准ILUMYA（tildrakizumab）用于治疗中重度斑块状银屑病, objectType=article, longId=149465, objectId=46e31494650f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46e31494650f, replyNumber=0, likeNumber=73, createdTime=2018-09-25, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46e31494650f, moduleTitle=澳大利亚TGA批准ILUMYA（tildrakizumab）用于治疗中重度斑块状银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46e31494650f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341118, encodeId=556c1341118f0, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性, objectType=article, longId=149073, objectId=52291490e33c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52291490e33c, replyNumber=0, likeNumber=79, createdTime=2018-09-20, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52291490e33c, moduleTitle=III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52291490e33c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341117, encodeId=5ab5134111efd, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=Kineret（anakinra）在英国批准用于罕见炎症性疾病的治疗, objectType=article, longId=144574, objectId=7bab1445e406, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bab1445e406, replyNumber=0, likeNumber=61, createdTime=2018-07-18, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bab1445e406, moduleTitle=Kineret（anakinra）在英国批准用于罕见炎症性疾病的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bab1445e406)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341116, encodeId=96791341116ae, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=Canakinumab可将痛风发生率降低一半以上, objectType=article, longId=141553, objectId=6dc41415536a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dc41415536a, replyNumber=0, likeNumber=63, createdTime=2018-06-26, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dc41415536a, moduleTitle=Canakinumab可将痛风发生率降低一半以上, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dc41415536a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341115, encodeId=4d8a134111545, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=AKI+反复代谢性碱中毒1例, objectType=article, longId=136619, objectId=408013661952, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=408013661952, replyNumber=0, likeNumber=85, createdTime=2018-04-28, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=408013661952, moduleTitle=AKI+反复代谢性碱中毒1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=408013661952)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341114, encodeId=ab571341114f4, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=J Am Soc Nephrol：AKI住院后的死因, objectType=article, longId=133883, objectId=0774133883e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0774133883e4, replyNumber=0, likeNumber=59, createdTime=2018-04-01, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0774133883e4, moduleTitle=J Am Soc Nephrol：AKI住院后的死因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0774133883e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341113, encodeId=647e13411136f, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=JASN：心脏手术后儿童AKI进展的生物标志物！, objectType=article, longId=131129, objectId=b768131129a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b768131129a3, replyNumber=0, likeNumber=66, createdTime=2018-03-03, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b768131129a3, moduleTitle=JASN：心脏手术后儿童AKI进展的生物标志物！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b768131129a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341112, encodeId=d863134111218, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=Int J Cardiol：术中低血压与非心脏手术后30天死亡率、MACE和AKI相关！, objectType=article, longId=128671, objectId=581a1286e1d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=581a1286e1d0, replyNumber=0, likeNumber=59, createdTime=2018-02-04, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=581a1286e1d0, moduleTitle=Int J Cardiol：术中低血压与非心脏手术后30天死亡率、MACE和AKI相关！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=581a1286e1d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

AKI

2020-05-29

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

Blueprint的Ayvakit成为美国获批治疗罕见胃肠道间质瘤突变的靶向疗法

2020-01-12

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

礼来的聚乙二醇白细胞介素-10（pegilodecakin）在胰腺癌临床试验中失败

2019-10-22

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

免疫疗法pegilodecakin在胰腺癌中的III期研究未能达到总体生存的主要终点

2019-10-19

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

J Endod：Gow-Gates, Vazirani-Akinosi和Mental Incisive神经阻滞对有症状不可逆牙髓炎的麻醉效果比较

2019-10-04

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

Lancet oncol：Pegilodecakin联合抗PD-1单克隆抗体是否可为晚期实体肿瘤提供新的治疗机会？

2019-09-28

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

Harmony Biosciences的嗜睡症治疗药物Wakix获得FDA批准

2019-08-18

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

庆大霉素诱导的AKI大鼠给予麝香酮骨髓间充质干细胞可提高其治疗效果

2019-04-29

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

英国NICE推荐Akice公司的反义寡核苷酸药物Tegsedi用于治疗罕见遗传病：转甲状腺素相关的淀粉样蛋白变性

2019-04-19

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

Daiichi Sankyo的EZH1/2双重抑制剂Valemetostat获得日本厚生劳动省SAKIGAKE指定，用于治疗复发/难治性外周T细胞淋巴瘤

2019-04-11

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

成纤维细胞生长因子受体酪氨酸激酶抑制剂E7090治疗胆管癌，获得日本厚生劳动省的Sakigake指定

2019-04-10

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

SanBio宣布其再生细胞疗法SB623治疗创伤性脑损伤，获得日本厚生劳动省Sakigake指定

2019-04-10

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

Crit Care：利尿剂有助于AKI重症患者成功停用CRRT？

2018-11-01

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

澳大利亚TGA批准ILUMYA（tildrakizumab）用于治疗中重度斑块状银屑病

2018-09-25

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性

2018-09-20

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

Kineret（anakinra）在英国批准用于罕见炎症性疾病的治疗

2018-07-18

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

Canakinumab可将痛风发生率降低一半以上

2018-06-26

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

AKI+反复代谢性碱中毒1例

2018-04-28

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

J Am Soc Nephrol：AKI住院后的死因

2018-04-01

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

JASN：心脏手术后儿童AKI进展的生物标志物！

2018-03-03

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

Int J Cardiol：术中低血压与非心脏手术后30天死亡率、MACE和AKI相关！

2018-02-04

科室
- - 订阅+
  - 更多科室
工具
服务